Abstract
Introduction EGFR-TKIs have been shown in multiple clinical trials to be effective in first-line therapy, but acquired resistance is inevitable regardless of the recent effect. EGFR-TKIs combined with TCM comprehensive therapy have shown unique effects in clinical randomized trials to increase the efficacy of radiotherapy and chemotherapy and gene-targeted drugs, reduce their adverse reactions, reduce the chance of recurrence and metastasis, enhance the immune recognition and killing of lung cancer cells, and reverse the multi-drug resistance of lung cancer cells. Therefore, our study aims to clarify the clinical efficacy, safety and benefit of EGFR-TKIs combined with TCM in the treatment of advanced non-small cell lung cancer.
Methods and Analysis We will search four international electronic databases (PubMed, Cochrane Library, EMBASE and Web of Science) and four Chinese electronic databases (CNKI, VIP, WanFang, China Biology Medicine) to retrieve relevant literature. We only included studies from launch until publication in May 2022. The primary outcomes will include the Response Evaluation Criteria in Solid Tumours、 progression-free survival and effectiveness rate。 Secondary outcomes will include Karnofsky functional status scale, 1-year survival rate, and grading scale for common toxicities of anticancer drugs(WHO). Two reviewers will conduct independent research selection, data extraction, data synthesis and quality assessment. The assessment of bias risk and data synthesis will be conducted using Review Manager 5.3 software. Improved Jadad scale will be used to evaluate the quality of evidence.
Ethics and Dissemination Because this systematic review will be conducted based on published research, there is no ethical approval requirement. The findings of this systematic review will be published in a peerreviewed journal.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Because this systematic review will be conducted based on published research, there is no ethical approval requirement.The findings of this systematic review will be published in a peerreviewed journal.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
Author: Shanyang Su, professional master’s student. Research Interests: Integrative Medicine in the Treatment of Respiratory Diseases. E-mail: 1513235594{at}qq.com
Data Availability
Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.
